Drug
Alpelisib clinical trials
Also written BYL719, Piqray and VIJOICE.
- studies test it
- 81
- open now
- 14
- in phase 3
- 8
- first study started
- 2010
Keep track of what changes. Save the Alpelisib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
81 studies that test it; most in 2014 (10)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 6 |
| 2013 | 3 |
| 2014 | 10 |
| 2015 | 6 |
| 2016 | 6 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 9 |
| 2022 | 8 |
| 2023 | 10 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 39
- Phase 2
- 39
- Phase 3
- 8
- Phase 4
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 36 · Other 45
Novartis Pharmaceuticals (31) · Columbia University (4) · M.D. Anderson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · Peter MacCallum Cancer Centre, Australia (2) · National Cancer Institute (NCI) (2) · UNICANCER (2) · Pamela Munster (2)
Often tested with
Tested in the same studies.
Fulvestrant (11) · Paclitaxel (8) · Ribociclib (6) · Trastuzumab (6) · Olaparib (6) · Palbociclib (5) · Everolimus (4) · Pertuzumab (4)
Studies
Open first, then newest update. How each study uses Alpelisib is read from its arms, and is right about nine times in ten.
Testing it · 81
- 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAsRecruitingPhase 2Children's Hospital of PhiladelphiaNCT07543822Written as alpelisib (BYL719)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Alpelisib
- Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.RecruitingPhase 2/3Novartis PharmaceuticalsNCT05948943Written as Alpelisib
- EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)RecruitingPhase 2Novartis PharmaceuticalsNCT06997588Written as Alpelisib
- Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)RecruitingPhase 1M.D. Anderson Cancer CenterNCT06545682Written as Alpelisib + Pembrolizumab
- Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Not yet recruitingPhase 2Novartis PharmaceuticalsNCT07679269Written as Alpelisib
- Alpelisib Challenge Test (ACT)RecruitingPhase 1Columbia UniversityNCT07778524Written as Alpelisib 300 mg
- Human Models of Selective Insulin Resistance: Alpelisib, Part IRecruitingPhase 1Columbia UniversityNCT06354088Written as Alpelisib 300 mg
- A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular MalformationsRecruitingPhase 2Murdoch Childrens Research InstituteNCT05983159Written as Alpelisib
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308Written as alpelisib+fulvestrant
- Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)RecruitingPhase 2Centre Hospitalier Universitaire DijonNCT05577754Written as Alpelisib (BYL719)
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorRecruitingPhase 2Dartmouth-Hitchcock Medical CenterNCT05933395Written as Alpelisib
- Combination of Alpelisib and Trametinib in Progressive Refractory MeningiomasRecruitingPhase 1Assistance Publique Hopitaux De MarseilleNCT03631953Written as Alpelisib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Alpelisib
- Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation DetectedTerminatedPhase 3Novartis PharmaceuticalsNCT04729387Written as Alpelisib
- Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedPhase 3Spanish Breast Cancer Research GroupNCT05063786Written as Alpelisib
- Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)Active, not recruitingPhase 2Novartis PharmaceuticalsNCT04980833Written as Alpelisib
- Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or RibociclibTerminatedPhase 2UNICANCERNCT05625087Written as Alpelisib
- Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth SpectrumActive, not recruitingPhase 2Novartis PharmaceuticalsNCT04589650Written as Alpelisib
- Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05038735Written as Alpelisib
See all 81 studies that test Alpelisib →
Given in every arm · 11 — Alpelisib is usual care beside what is tested
- Preventing High Blood Sugar in People Being Treated for Metastatic Breast CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05090358Written as Alpelisib
- A Study of Alpelisib and Fulvestrant to Treat Endometrial CancerActive, not recruitingPhase 2GOG FoundationNCT05154487Written as Alpelisib Pill
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingPhase 1Eli Lilly and CompanyNCT04188548Written as Alpelisib
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruitingPhase 1/2Stemline Therapeutics, Inc.NCT05563220Written as Alpelisib
- SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)Active, not recruitingPhase 2Borstkanker Onderzoek GroepNCT05392608Written as Alpelisib 150 MG Oral Tablet [Piqray]
- Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior TreatmentsCompletedPhase 2Novartis PharmaceuticalsNCT03056755Written as Alpelisib
- Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast CancerTerminatedPhase 1/2SanofiNCT03284957Written as Alpelisib
- Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC PatientsCompletedPhase 2MedSIRNCT04300790Written as Alpelisib
- BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast CancerCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT01870505Written as BYL719
- Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and FulvestrantTerminatedPhase 2Novartis PharmaceuticalsNCT04899349Written as Alpelisib
- Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic TumorsCompletedPhase 1Novartis PharmaceuticalsNCT02077933Written as alpelisib
As the comparator · 2 — what is tested is compared with Alpelisib
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyRecruitingPhase 3Hoffmann-La RocheNCT05646862Written as Alpelisib
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)Active, not recruitingPhase 3Celcuity IncNCT05501886Written as Alpelisib
Codes
What other systems call Alpelisib · ClinicalTrials.gg INT006407
- MeSH (NLM) C585539AlpelisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 08W5N2C97QALPELISIBConfirmed FDA, NLM, Wikidata
- RxNorm 2169285Confirmed FDA, Wikidata
- Wikidata Q27074391alpelisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C94214AlpelisibOne source FDA
- DrugBank DB12015One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585539 | Alpelisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 08W5N2C97Q | ALPELISIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2169285 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27074391 | alpelisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C94214 | Alpelisib | One source FDA |
| DrugBank | DB12015 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.